SeekingAlpha · Aug 12, 2026
RadNet: Imaging And AI Keep The Bull Case Intact
RadNet's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. Read why RDNT stock is a Strong Buy.
RD
NASDAQ · RDNT
RadNet, Inc.
Healthcare · Medical - Diagnostics & Research
$76.82
Down-$0.23 (-0.30%)
Updated Aug 22, 2026, 3:28 AM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 6.07B
- P/E ratio
- -462.56
- Dividend yield
- 0.00%
- 52-week range
- $50.82 – $78.86
- Volume
- 644.95K
- Avg. volume
- 753.34K
Price performance
RDNT price history
1M range · 0 trading sessions · Daily adjusted prices
RDNT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest RDNT news
The latest Smart Investors Daily articles mentioning RDNT.
Stock researchCompany · Overview
RDNT research
Overview
Company profile and research snapshot.
Company profile
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $88.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Truist Securities | Buy | — |
| May 20, 2026 | Barclays | Overweight | — |
| Apr 21, 2026 | Barclays | Overweight | — |
| Jan 9, 2026 | Keybanc | Overweight | — |
| Dec 1, 2025 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 11, 2026
RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised
RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.
Benzinga · Aug 11, 2026
Truist Securities Maintains Buy on RadNet, Raises Price Target to $94
Truist Securities analyst David Macdonald maintains RadNet (NASDAQ:RDNT) with a Buy and raises the price target from $90 to $94.
Yahoo · Aug 11, 2026
RadNet (RDNT) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be announcing earnings results next tomorrow after market close. Here’s what to look for.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
